(5Z)-3-(4-Chlorophenyl)-5-[(4-chlorophenyl)methylidene]-2-sulfanylideneimidazolidin-4-one

Catalog No. :
ACUKYA351
CAS No. :
55338-20-0
Molecular Formula :
C16H10Cl2N2OS
Molecular Weight :
349.24

IUPAC Name:(Z)-5-(4-chlorobenzylidene)-3-(4-chlorophenyl)-2-thioxoimidazolidin-4-one

(5Z)-3-(4-Chlorophenyl)-5-[(4-chlorophenyl)methylidene]-2-sulfanylideneimidazolidin-4-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$215.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(5Z)-3-(4-Chlorophenyl)-5-[(4-chlorophenyl)methylidene]-2-sulfanylideneimidazolidin-4-one
IUPAC Name(Z)-5-(4-chlorobenzylidene)-3-(4-chlorophenyl)-2-thioxoimidazolidin-4-one
MDL No.MFCD00975550
Molecular FormulaC16H10Cl2N2OS
Molecular Weight349.24
SMILESO=C(/C(N1)=C/C2=CC=C(Cl)C=C2)N(C3=CC=C(Cl)C=C3)C1=S
InChI KeySJMHOIBGDQLPFB-ZROIWOOFSA-N
Synonym3-(4-CHLOROPHENYL)-5-[(4-CHLOROPHENYL)METHYLENE]-2-THIOXOTETRAHYDRO-4H-IMIDAZOL-4-ONE;(5Z)-3-(4-chlorophenyl)-5-[(4-chlorophenyl)methylidene]-2-sulfanylideneimidazolidin-4-one;4-Imidazolidinone, 3-(4-chlorophenyl)-5-[(4-chlorophenyl)methylene]-2-thioxo-
CAS No.55338-20-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACUKYA351 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACUKYA351 route product structure diagram
    ACUKYA35155338-20-0
Inquiry

2. ACUKYA351 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUKYA351 route product structure diagram
    ACUKYA35155338-20-0
Inquiry

Comments (0)